Herpes Labialis

Phase 2 study of herpes labialis treatment successfully completed

Published in Hepatitis Weekly, August 15th, 2005

NanoBio Corporation announced that it has successfully completed its phase 2 study of NB-001 in patients with herpes labialis (cold sores) and is moving ahead with plans to conduct phase 3 clinical trials next year.

NB-001 is a topical emulsion comprised of nanometer-size water/oil droplets coated with a surfactant that has demonstrated potent antiviral, antibacterial and antifungal activity in previous studies. These uniformly small antimicrobial particles are designed to accelerate the healing of skin ulcers by killing the herpes viruses at the lesion site.

The multi-center phase 2 study enrolled 332 patients with recurrent herpes labialis who were...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2005-08-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry